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Abstract 
The susceptibility of individuals to obesity has been reported in many developed countries with 
predisposition of humans to obesity associated with high calorie diets and unhealthy lifestyles. 
Obesity may closely be involved in cell suicide in various organ diseases with the importance of 
accelerated aging that requires early intervention with drug therapy to prevent diseases such as 
non alcoholic fatty liver disease (NAFLD) that has increased in children and reached to approx. 
40% of the global population. Obesity is induced by various diets and lifestyle factors such as 
stress, anxiety and depression which are important to consider with the global increase in obesity 
and are possibly linked to the rise in individuals with brain disorders that involve neurodegene-
ration. Xenobiotics such as the endocrine disruptor chemicals that have increased in the environ-
ment in various developed countries lead to various chronic endocrine diseases as populations 
divert towards unhealthy diets and lifestyles with induction of NAFLD and obesity. The amount 
and nature of food intake that improves and increases liver lipid and xenobiotic metabolism in 
obese individuals have become important to decrease the risk for increased adiposity in man. 
High fibre or protein diets that contain leucine may improve liver glucose, lipid and xenobiotic 
metabolism and require further investigation with xenobiotics such as endocrine disruptors in-
volved in appetite dysregulation and metabolic disorders in developed countries. The use of 
anti-obese drugs that reduce food intake and improve hypercholesterolemia and cardiovascular 
disease has been assessed in obesity with drug therapy closely involved either in the prevention 
or induction of NAFLD and obesity in man. 
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1. Introduction 
The projected health care costs by the year 2018 in relation to obesity related medical expenses in the United 
States have been reported to be 344 billion dollars accounting for 21% of total health care costs. In particular, 
intra-abdominal adipose tissue referred to as visceral fat has been associated with the metabolic syndrome and 
obesity associated with insulin resistance and an increase in the cardiovascular risk factors such as dyslipidemia, 
hypertension and Type 2 diabetes [1]-[4] in women being more at risk than men in various countries. The sus-
ceptibility of humans to obesity is far higher compared with other species and in man favours the deposition of 
fat. Amongst mammals, humans have been reported to have the highest levels of fat than any other species and 
genes and environmental factors predispose humans to obesity. The global increase in obesity is linked to vari-
ous induction factors such as dietary fat that override the liver’s ability to metabolize lipids and determine 
excess body fat (adipose tissue size) with the risk of hypercholesterolemia and insulin resistance that lead to 
population mortality in developed countries.  
In developed countries, the Western diet is known to be high in fat and glucose and associated with an in-
crease in NAFLD and obesity [5]-[7]. There has been a rise in obesity over the past decades with the death rate 
from the complication of obesity in the United States to be approx. 300,000 per year. Obesity is second only to 
smoking as preventable cause of death and the number of obese individuals is expected to rise to approx. 42% of 
the population by the year 2030. The prevalence of childhood and adolescent obesity has tripled since 1980 in 
several age groups and the prevalence of overweight or obesity exceeds 50%. In North America, the rate of 
childhood obesity has doubled in the last 20 years and similar statistics are reported in countries like Thailand, 
China, Brazil and South Africa. 
Several modalities that prevent the induction of obesity have been tested which include diets, drugs, exercise 
and behaviour. In mice, induction of obesity has become important and the models have been created to study 
obesity and its co-morbidities such as Type 2 Diabetes, hypertension, hypercholesterolemia and atherosclerosis as 
found in man. In reports related to cardiovascular disease and threats to global health, various diets and drugs have 
been considered because of their ability to regulate genes linked to human adiposity that are closely linked to life 
extension in man [8] [9]. Early dietary intervention in obese mice models allowed reduction in the severity of 
visceral obesity and several chronic diseases such as NAFLD and neurodegenerative diseases [10]-[14]. Interests 
in the use of anti-obesity drugs have increased since successful therapy may reduce the complications such as the 
risks of diabetes and cardiovascular disease that have been reported with obesity. Education programs such as 
food restriction programs have been performed but induction of obesity has not decreased in the developed world 
[7]. Morbid obesity has gained attention and bariatric surgery or gastric banding has been used however the need 
for reoperation in these morbid individuals indicates discomfort and complications of the surgery. Interventions in 
obesity that reverse the induction processes allow normal gene regulation of tissues with increased lipid and 
xenobiotic (drugs, and chemicals) metabolism in tissues such as the liver that is central to adiposity and chronic 
disease progression with contribution to the global obesity epidemic. 
2. Adiposity and Obese Classifications 
Adiposity is the body fat tissue content and its increase is measured by body mass index (BMI). Obese individu-
als are defined as having a BMI of >30 (BMI = weight in kg/m2) [height inm] whereas overweights are defined 
as having a BMI from 25 - 30 kg/m2 and ideal lean individuals to have a BMI of 25 kg/m2. The role of the liver 
and the induction of obesity early in life are of critical understanding to the development of hyperinsulinemia 
which may lead to diabetes and other morbid diseases such as cancer and coronary artery disease. Visceral fat is 
more metabolically active than peripheral fat and is associated with Type 2 diabetes, dyslipidemia, high blood 
pressure, and increased risk for atherosclerotic disease [8] [9]. The waist-to-hip ratio helps identify patients with 
excess visceral adiposity. Women with a waist-to-hip ratio >0.8 and men with a ratio >1.0 are considered to have 
excess central adiposity that confers risk for developing the metabolic syndrome. Morbid obesity is classified as a 
BMI of >35 kg/m2 and severe obesity >40 kg/m2. In the United States, the number of children and young adults 
affected by Type 2 Diabetes has risen and childhood obesity is now considered a major predictor of adult obesity 
and Type 2 diabetes. 
3. Changes in Lifestyles Lead to Adiposity and Various Chronic Diseases 
The reported epidemiological shifts in NAFLD and obesity demand elevated costs to health care in developed 
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countries as well as in those that are poor and underdeveloped [14]. Excessive caloric intake, genetic, environ-
mental inducing agents, and psychosocial factors all contribute to the cause of the reduced metabolism and de-
velopment of obesity in middle adult life. In the United States, prevalence of obesity has increased from 15% in 
1980 to 36% in 2010 with morbid obesity greater in women than men. In overweight individuals, obesity leads 
to inflammation and increased oxidative stress in the brain and periphery and has prompted intense research in 
the induction of various other chronic diseases in organs such as heart, pancreas, thyroid, kidneys, reproductive 
organs, lungs and brain [15]-[23]. Lifestyles that involve increased anxiety and stress in individuals in developed 
countries induce obesity with a shorter life span and worldwide approx. 2.5 million deaths result from various 
chronic diseases in peripheral organs with obese women more at risk than men in developed countries [24].  
In the developed communities, obesity is one of the major causes of atherosclerosis, stroke [25] and heart 
failure with approx. 13% of individuals ending in death. In severe obese individuals, sudden cardiac death can 
be as high as 40 times in obese men than women and arrhythmia accounts for the mortality. Hypertension and 
obesity are closely linked with 42% of individuals with blood pressure dysfunction. Disorders of the pancreas 
are closely linked to insulin resistance with the metabolic syndrome responsible for various organ diseases such 
as diseases of the kidneys [22] [23], reproductive organs, lungs and thyroid (hypothyroid). Menstrual cycle dis-
orders and infertility are closely correlated with obese women. Obese men have fertility problems with abnormal 
semen outputs related to endocrine alterations such as adipokines, sex steroids and insulin resistance. Respirato-
ry diseases such as chronic obstructive pulmonary disease, asthma, obstructive sleep apnea and obesity hypo-
ventilation syndrome are associated with obesity. The relationship between increasing obesity and decreasing total 
lung capacity has been reported. Hypothyroidism is linked to reduced metabolism and energy expenditure with 
increased adiposity in obese individuals. 
In obesity, low brain volumes and central nervous system alterations are possibly associated with an increased 
incidence of stroke independent of other risk factors such as diabetes, hypertension and hypercholesterolemia. 
Body fat disturbances and their association with brain disorders have previously been assessed with regional al-
terations in brain structure [26] [27] and a reduction in brain volume determined by voxel based morphometry 
(VBM). This technique analyses the whole brain and is based upon 3D magnetic resonance imaging (MRI) with 
objective assessment of the neuroanatomical structure throughout the brain. Obese individuals compared with 
lean individuals have significantly lower gray matter density in the post central gyrus, frontal operculum, puta-
men and middle frontal gyrus after adjustment for sex, age, handedness and global tissue density. BMI in these 
obese individuals was negatively associated with GM density of the left post central gyrus in comparison with 
that in lean subjects. This study identified structural brain differences in human obesity in several regions of the 
brain that are involved in the regulation behaviour, reward and taste with increased weight gain in obesity. In 
childhood, obesity with the metabolic syndrome disorder changes in brain volume and structure may also indi-
cate alterations in appetite, hypertension and insulin resistance closely associated with brain abnormalities in 
obese children [28]. Furthermore, the increased risk between obesity and neurodegeneration in the developed 
world has been shown in a 27 year longitudinal study [29].  
In obese individuals, loss of brain control is poorly understood and alterations in brain circuitry or feeding 
signals in obesity involve abnormal hormone regulation with poor control of chronic organ disease progression. 
The hypothalamus is involved in many biological functions such as appetite and body weight control, feeding, 
rhythmic daily activities and corticosteroid regulation [10]. In obese individuals, loss of the ability of the brain 
to regulate body weight and energy balance is dependent on neurons in the hypothalamus and their connections 
to various brain regions that are abnormal in chronic neuroendocrine diseases such as in obesity and diabetes [10]. 
In obesity, the brain disorders include the hypothalamus with suprachiasmatic nucleus (SCN) disorders that in-
volve the neural and humoral systems and arcuate nucleus neurons involved in the generation of circadian 
rhythms with releases of neuropeptide Y (NPY) and agouti related protein (AgRP) that control physiological 
functions such as appetite regulation and behavioural functions [10] [30]-[32]. The SCN releases a number of 
hormones and the SCN projects to the dorsal parvocellular paraventricular nucleus which projects to sympathetic 
preganglionic neurons with regulation of melatonin output from the pineal gland. Changes in lifestyle pattern, diet 
intake and usage of drugs induce various peripheral organ diseases, leading to disturbances in SCN neurons ex-
pressing neuropeptides [10], causing elevations in peripheral signals such as glucose, amino acids, fatty acids, 
cholesterol, and amyloid beta, with alterations in peripheral hormones such as leptin, adiponectin (adipose tissue) 
and ghrelin, that have marked effects on the brain control for appetite regulation, energy expenditure and meta-
I. J. Martins 
 
 93 
bolism [33]-[37]. Peripheral organ diseases such as chronic kidney disease are associated with SCN disturbances 
with the role of melatonin in the treatment of chronic kidney disease [38]. In particular. high fat diets and 
alcohol are linked with SCN disturbances and consumption of these diets induces circadian alterations in the 
brain linked to alterations in mental health and peripheral organ diseases. Adiposity and lifestyle changes such 
as circadian rhythms are linked to brain circadian disturbances induced by jet lag, lifestyles disturbances, drugs 
and diet [39] [40] and these environmental effects (Western countries) have become important and are now 
strongly linked to the development of human obesity in various developed countries. The SCN may regulate the 
sleep-wake cycle with effects on anxiety, stress and depression and these effects on the sleep-wake cycle have 
been shown to be species-specific. Sleep and chronic diseases possibly involve the hypothalamus and mela-
nin-concentrating hormone (MCH) that regulate metabolic homeostasis [10], sleep and wakefulness [41]. Fur-
thermore in obesity, melatonin released from the pineal gland during the night is disrupted during sleep with sleep 
dysregulation [42] and loss of entrainment of the SCN [43]. 
Alterations in sleep patterns in health and disease are involved in changes in adiposity since disrupted sleep 
patterns affect the 24 hr clock in the brain that is controlled by the SCN in the hypothalamus. Sleep deprivation 
may be involved in the induction of obesity [44]-[47] and has been shown to be related to the circulating levels of 
the appetite stimulating hormone ghrelin and leptin contents [48]. Furthermore, appetite regulating hormones 
such as ghrelin and leptin can influence these areas of the brain and are involved with resetting the circadian 
rhythms generated by the SCN. These hormonal changes in sleep-deprived adults are possibly related to increased 
body weight in these obese individuals. Anxiety and stress disorders may induce sleep disturbances that affect 
mental health that induces changes in the brain, hormone regulation and the biological clock in the body. 
4. Unhealthy Nutrigenomic Diets Accelerate NAFLD and Adiposity in Developed  
Countries 
The understanding of genetic factors involved in the risk for obesity has identified genes that are closely linked to 
obesity related diseases [49]-[52]. A single gene effect versus multiple genes effect may indicate either the inte-
raction unique to various environments that regulate abnormal molecular or cellular events responsible for obesity 
with several hypotheses proposed in relation to the development of obesity [53]. The understanding of the de-
velopment of adipogenesis has been the focus of various research groups with unhealthy diets that alter DNA 
methylation (epigenetic), genes and transcription factors important to the world-wide obesity epidemic with in-
creased risk for adiposity. Alterations in 400 genes, single gene disorders and variants are involved in obesity 
with particular genes (e.g. leptin, melanocortin/Melanocortin 4 receptor, ghrelin, neuromedin β, peroxisome pro-
liferator-activated receptor (PPAR), and mitochondrial uncoupling proteins) involved in the behaviour, meta-
bolism, energy expenditure, taste and appetite of the organism.  
The search for specific genes that are sensitive to nutritional regulation, oxidative stress, inflammation, endo-
crine disease, lipid/glucose metabolism and insulin resistance has been the focus of the current obesity epidemic 
in various developed countries. Epigenetics is now considered as an important mechanism for the development of 
obesity and can result from changes in cellular chromatin structure without alterations in DNA sequence, in-
cluding DNA methylation, histone modifications and chromatin remodelling. Epigenetic modifications altered by 
unhealthy diets with increased oxidative stress or environmental factors have the ability to change gene expression 
with effects on cellular lipid metabolism and energy expenditure. Epigenetic modifications in Western commun-
ities are closely involved in early liver disease (NAFLD) associated with excess transfer of fat to the adipose 
tissue and the induction of obesity in developed countries. 
Sirtuin 1 (Sirt1) is one of the nuclear receptors known to regulate several cell functions by deacetylating both 
histone and non-histone targets and this anti-aging gene [54] in the liver is either inhibited or suppressed in 
Western populations with accelerated aging of the liver (NAFLD) and profound effects on the health of other 
organs. Sirt1 is a NAD(+)dependent class III histone deacetylase (HDAC) protein that targets transcription 
factors to adapt gene expression to metabolic activity, insulin resistance and inflammation in chronic diseases 
[55]-[59]. Nutritional regulation (calorie restriction and high fat feeding) of Sirt1 that is involved in the hypo-
thalamic control of food intake with regulation of the central melanocortin system via the fork head transcription 
factor has been reported [60]-[63]. Sirt1 has been closely linked with alterations in appetite regulation and circa-
dian rhythms that have been associated with obesity and alterations in Sirt1 expression and leptin levels have 
been associated with disruption of the daily light/dark cycle. In support of Sirt1’s role in circadian rhythms 
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[64]-[68] subjects carrying minor alleles at Sirt1 and CLOCK loci displayed a higher resistance to weight loss 
compared with homozygotes for both major alleles, suggesting links between the circadian clock and Sirt1 function. 
Other genetic studies provide strong links between obesity and Sirt1 gene polymorphisms. These genetic studies 
provide a greater understanding of Sirt1 polymorphisms and individuals that may be at increased risk for obesity. 
Diets and nutrigenomics are involved in Sirt1 regulation that is actively involved in DNA repair with 
transcription factors regulated by Sirt1 in obesity closely connected to the nuclear hormone receptors such as 
peroxisome proliferator activated receptor (PPAR), liver X receptor (LXR), pregnane X receptor (PXR), farne-
soid X receptor (FXR) involved in liver metabolic and xenobiotic homeostasis [14] with roles in lipid metabol-
ism in adipose tissue. In adipose tissue, Sirt1 triggers fat mobilisation by inhibiting peroxisome proliferator- 
activated receptor gamma (PPAR-gamma), and in the pancreas, Sirt1 repression of the uncoupling protein 2 
(UCP2) increases insulin secretion and also influences mitochondrial biogenesis and inflammation. Sirtuins are 
involved in gluconeogenesis in the liver, fat mobilisation from white adipose tissue, cholesterol metabolism, 
insulin secretion from the pancreas and energy metabolism. Excess calorie consumption leads to liver Sirt1 
downregulation that causes liver disease (NAFLD) with the excess fatty acid and cholesterol transported to the 
adipose tissue and peripheral organs. The concept that high fat diets can downregulate Sirt1 levels in the liver 
may have important implications for the role of the liver in the induction of obesity in man with excess fat 
transport to the adipose tissue.  
Sirt1 is involved in endocrine and somatotrophic disturbances that implicate growth hormone in insulin resis-
tance and peripheral endocrine disease [69]-[72]. Furthermore, Sirt1 is downregulated by palmitic acid and al-
cohol and its low activity is involved in various chronic diseases (metabolic syndrome) of the lung, heart and 
kidney [73]-[75]. Cellular Sirt1 expression/activity is important in the processing of amyloid precursor protein 
which generates the AD peptide amyloid beta in neurons with links to neurodegenerative diseases. The link be-
tween obesity, food intake and amyloid beta [76] homeostasis under circadian control indicates that disturbances 
in the SCN in chronic diseases such as obesity and diabetes also possibly involve neurodegenerative diseases 
such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). 
Transcription factors and gene regulators include micro RNA (miRNAs) and their role in the induction of ob-
esity indicates altered expression of multiple miRNAs in metabolic tissues [77]. MiRNAs 103 and 143 are im-
portant in the acceleration of adipogenesis [78] with other miRNAs such as miR-27 and miR-519d [79] by reg-
ulation of PPAR determine adipocyte development and fat cell numbers. PPARγ is strongly expressed in adipo-
cytes and plays a significant role in the transcriptional activation of adipocytokines (adiponectin and leptin). 
PPARα activation causes increased lipid clearance via β-oxidation enhancement and miRNA dysregulation is 
important in the abnormal metabolism of adipocyte lipids and the development and severity of obesity. Dietary 
regulation of Sirt1 expression in adipose tissue may play a central role in NAFLD with the effects of miRNA 
deregulation in Sirt1 regulation involved in insulin resistance and metabolic disease [80] [81]. 
5. Induction of Obesity and NAFLD in Rodent Obese Models with Relevance to Man 
Animal models of obesity resemble human obesity with hyperphagia (overeating), hyperinsulinemia, hyperlipi-
demia and NAFLD [82]-[91]. To assess the induction of obesity in experimental animals, confounding factors 
such as genetic diversity, gender, diet and age that are involved in the induction of human obesity can be con-
trolled in animal models [91]. Mice fed a high fat diet or high fat/high sugar diet over a number of weeks be-
come obese and insulin resistant. These obese mice are used to study the genetic and physiological mechanisms 
of obesity that are similar to conditions in humans. Rodent and human models for obesity vary with factors that 
include the species, strain, genetic models, age of animals and type and amount of fat consumed. There are sev-
eral causes of obesity in rodent models and obesity may result from the excessive food intake or slow body fat 
metabolism (Table 1). 
Obesity can be chemically induced by gold thioglucose (GTG) by development of lesions in the brain [91] 
and other tissues (e.g. liver, kidneys and adipose tissue). The GTG mice are hyperinsulinemic and within 5 
weeks become overweight associated with a number of insulin receptors [91]. Genetic models of rodent obesity 
also include the obese/obese (ob/ob) mouse, fat/fat, yellow-obese mouse, diabetic (db/db) and the New Zealand 
Obese mouse [91]. In all models of obesity (chemically induced or genetic) in our studies, food intake markedly 
increased (hyperphagia) with a decrease in the hepatic metabolism of lipid particles [91]-[93]. Marked im-
provements in the hepatic lipid metabolism with food restriction were associated with improved plasma glucose 
and lipid levels indicating food restriction to be closely linked to the maintenance of hepatic lipid and glucose  
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Table 1. Induction of obesity in mice with insulin resistance and organ dysfunction.                                  
INDUCING AGENTS APPETITE DISORDER OXIDATIVE STRESS 
METABOLIC DISEASE 
ORGAN DISEASE 
HIGH FAT HIGH CHOLESTEROL DIETS YES PANCREAS, NAFLD, BRAIN, ADIPOSE TISSUE, THYROID 
HIGH SUGAR CARBOHYDRATE  DIETS YES PANCREAS, NAFLD, BRAIN, ADIPOSE TISSUE, THYROID 
CHEMICAL AGENTSEg. Goldthioglucose, Eg. 
Endocrine disrupting chemicals YES 
PANCREAS, NAFLD, BRAIN, ADIPOSE 
TISSUE, THYROID 
GENETIC OBESE/DIABETIC MODELS YES PANCREAS, NAFLD, BRAIN, ADIPOSE TISSUE, THYROID 
 
metabolism. In our studies of obese mice and streptozotocin induced diabetic rats [93], the clearance of li pid 
particles was also markedly decreased and prevention of hyperphagia improved the clearance of lipids and lo-
wered plasma glucose levels. In these obese mice and diabetic rats, the diet contained 5% fat (low fat) but food 
intake over the 6 week experimental period was twice that of the controls [92] [93]. In both chemical and genet-
ic mouse models of obesity, the mice developed hyperphagia with nutrition stress and NAFLD and the slow liv-
er metabolism of lipids was possibly associated with Sirt1 mediated cell apoptosis associated with poor appetite 
control [92] [93]. Relevance to man with stable isotope breath tests showed that the poor metabolism of hepatic 
lipid particles was possibly linked to NAFLD and obesity in man [94]-[96]. In mouse models of obesity, induc-
tion by diet was closely linked to NAFLD in these mice [87]-[89]. The studies in obese mice, diabetic rats and 
obese man clearly indicated that the abnormal glucose and hepatic lipid metabolism may be closely linked to 
reduced hepatocellular Sirt1 activity and expression with induction of NAFLD. 
Lifestyle patterns, environmental stress and diets (nature of fat/carbohydrates) may hamper the hepatic xeno-
biotic metabolism [14] of various pollutants such as endocrine disrupting chemicals (EDC) and drugs with close 
connections to disruption in energy homeostasis and increased risk for chronic disease. In experimental studies, 
models of lipid particles (chylomicron remnants) of different sizes that preferentially target the liver showed that 
the increased dose of injected lipids was related to the decreased clearance of lipid particles with possible effects 
on downregulation of hepatic Sirt1 activity [97]. The implications of reduced hepatic Sirt1 activity by nutritional 
regulation (chylomicron remnants) possibly are connected to the impaired intracellular hepatic metabolism of 
xenobiotics such as the EDCs [98]-[106] that is also under Sirt1 regulation [14]. Implications to diets that contain 
saturated fats (palmitic-rich) may lead to increased inhibition of nuclear Sirt1 activity by palmitic acid [107] [108] 
with decreased liver xenobiotic metabolism and induction of obesity and other chronic diseases. Increased levels 
of xenobiotics in the plasma and various tissues [14] may lead to increased reactive oxygen species associated 
with low Sirt1activity [109] [110] which is associated with obesity in developing countries. In developed coun-
tries, obese individuals may develop Sirt1 inhibition early in life that leads to liver dysfunction (NAFLD) and an 
increase in adipose tissue mass similar to that found in the Sirt1 knockout mouse with liver steatosis and increase 
in adipose tissue mass [111] [112]. In Sirt1 transgenic mice, over expression of Sirt1 leads to increased hepatic 
metabolic activity with reduction in blood lipids and glucose [113]. In children, the rise in NAFLD and obesity 
may indicate that epigenetic modifications by various xenobiotics may induce NAFLD associated with excess 
transfer of fat to the adipose tissue. Furthermore, the increased levels of certain xenobiotics such as persistent 
organic pollutants (POP) may be early risk factors for the induction of NAFLD and various chronic diseases in 
developed countries. 
6. Endocrine Disruptors as Risk Factors for Obesity and Chronic Disease 
Adipose tissue and endocrine dysregulation have become important to the understanding of the obesity asso-
ciated insulin resistance with relevance to chronic disease [10]. The link between NAFLD and endocrine dis-
rupting chemicals with the induction of obesity has become important since most EDCs or persistent organic 
pollutants (POP) are fat-soluble and dietary fat may accelerate their absorption and transport to the liver for me-
tabolism and degradation. EDC scan disrupt the metabolic and endocrine system by blocking or interfering with 
signals from nuclear receptors and cell receptors with the effects on endogenous hormones within various organs 
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of the body [98]-[100] [103]-[105]. Endocrine organs targeted by EDCs include the reproductive organs, heart, 
pancreas, thyroid, parathyroid, adrenal glands, hormone dependent metabolic system (pancreas and liver) and 
effects on brain function. Particular interest in EDCs such as phthalates in the regulation of the PPAR gamma 
(nuclear receptors) in adipose tissue indicates that they play an important role in the induction of obesity 
[114]-[119] similar to ceramide-PPAR interactions in cellular apoptosis and insulin resistance [10] [120]. The 
effects of EDCs on Sirt1-PPAR (alpha or gamma) interactions and their effects on the endocrine system have 
been reported with endocrine disorders linked to chronic diseases connected to appetite dysregulation and beha-
vioural disorders. 
Hypercholesterolemia and xenobiotic metabolism are now closely associated with the liver as a central organ 
in the metabolism of EDCs, cholesterol, fatty acids, glucose and bile acids [14]. The liver nuclear hormone re-
ceptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are xenobiotic nuclear receptors 
involved in the transcription of liver drug metabolizing enzymes and transporters [14]. The PXR receptor shows 
remarkable amino acid variability between species (80%) and indicates that the role of diet may have an impor-
tant influence on survival of various species [121]. The role of PXR and CAR in drug metabolism and energy 
homeostasis has become important to individuals in the developed world [122]. PXR knockout mice develop liver 
steatosis, hyperinsulinemia, hyperleptinemia and hypoadiponectinemia consistent with the metabolic syndrome 
[123]. The mouse models of the Sirt1 knockout or the PXR knockout indicate defects in xenobiotic and choles-
terol metabolism which are possible explanations for the molecular mechanisms for induction of obesity in man 
and the increased global obesity epidemic. 
In obese individuals, the Sirt1 dysregulation associated with the defective lipid metabolism also involves the 
abnormal metabolism of EDCs and POP in various tissues that contain fat stores [103]. The understanding of 
Sirt1 regulation of PXR function [14] in xenobiotics metabolism is now required with important involvement of 
PXR in HDL cholesterol metabolism [124] [125]. Furthermore, the involvement of PXR in the diabetes has in-
creased with the involvement of various PXR agonists in glucose and lipid dysregulation [126] [127]. In obesity, 
the brain disorders that involve the SCN regulation of the sleep-wake cycle have possible connections to 
Sirt1dysregulation and effects on PXR and its role on energy and xenobiotic metabolism. In obese individuals, the 
associated neurodegeneration is possibly related to the influence of EDCs or POP and their effects on the SCN and 
life cycles [14] [128] are possibly related to NAFLD with influences on adipose tissue circadian rhythms that lead 
to obesity. The control of chronic diseases induced by EDC disturbances depends on diets and anti-obese drugs 
that target Sirt1/PXR disorders (Figure 1) that are linked to the induction of obesity, cardiovascular disease and 
various diseases that involve the chronic endothelial injury hypothesis [129]-[136]. 
The P-glycoprotein 1 (Pgp1) is an adenosine triphosphate (ATP) dependent protein involved in xenobiotic 
transport by the export of cellular drugs across membranes in the liver, blood brain barrier (BBB), intestine and 
kidney [137]-[141]. Effects of Pgp in tissues include effects on lipid homeostasis with the development of NAFLD 
and obesity in Pgp knockout mice [142]. In the Pgp knockout mice, liver steatosis and excess adipose tissue mass 
was associated with metabolic disruptions [142]. The Pgp is actively involved in cholesterol transport (ABCA1  
 
 
Figure 1. Xenobiotic effects on PPAR-Sirtuin 1 and Pregnane X receptor in- 
duce SCN disorders (appetite dysregulation), obesity, endothelial dysfunction 
and chronic disease.                                                
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mediated) in the cell membranes with transport of cholesterol to HDL and LDL [138] [139]. In AD, upregulation of Pgp is 
involved in the rapid clearance of amyloid beta from the brain with implications for Pgp as a therapeutic target for amyloid beta 
and xenobiotic clearance in the brain [143] [144]. Upregulation of Pgp activity in the liver is involved in PXR protein levels 
with implications of diet on PPAR-Sirt1/PXR interactions [145] [146] involved in regulation of Pgp mediated xenobiotic 
clearance in chronic diseases such as the kidney. The kidney is a central organ for amyloid beta, drug and foreign compound 
metabolism [147]-[149] with important consequences to kidney disease associated with the obesity epidemic in children and 
adults [150]. Unhealthy diets that promote NAFLD may accelerate kidney disease with delayed renal clearance of amyloid 
beta and xenobiotics (EDCs and POP) with associated SCN dysfunction and neurodegenerative diseases. 
7. Use of Anti-Obesity Drugs with Treatment or Induction of Obesity 
Drugs that have been developed for the treatment of obesity are either involved in the reduction of energy intake or 
the increase of energy expenditure and their beneficial effects may include improvements in glycemic control or 
psychiatric illness. Interests in the use of obesity drugs have increased since safety and use of the drugs for con-
tinued weight loss (reduced visceral fat stores) have become of concern to medical authorities in Western com-
munities [151]-[154]. The continued use of the anti-obesity drugs has been assessed in relation to diabetes and 
cardiovascular disease and the weight loss events have not necessarily been associated with improved medical 
complications in obese women that are more at risk than men in various developed countries. 
Anti-obesity drug development has targeted the neurobiology of appetite [155] [156] and energy homeostasis 
and has different targets in the central nervous system (CNS) and peripheral nervous system (Figure 2). The role 
of anti-obesity pharmacotherapy is to control fat intake and reduce metabolic disorders such as the metabolic 
syndrome. The CNS drugs control food intake by acting on satiety by catech-cholaminergic noradrenaline and 
dopamine (e.g. diethylpropion, methamphetamine) pathways, 5 hydroxytrptamine pathway or combined path-
ways with receptors for control of satiety in the hypothalamus. Peripherally acting drugs act to reduce fat intake at 
the gastrointestinal tract or directly at the sympathetic nervous system by regulation of energy expenditure by 
thermogenesis or by lipolysis. 
The use of obesity drugs and their mechanisms of action may not be complete since the understanding the brain 
circuits and stabilization of neuroanatomical structures in the brain has not as yet been determined. The research in 
understanding the use of anti-obesity drugs in the stabilization of brain structures such as frontostriatal limbic 
circuits, hypothalamus brainstem circuits and parasympathetic nervous system is required and information of how 
neuropeptides and neurotransmitters are regulated by these drugs requires further assessment. Various anti-obe- 
sity drugs that target the CNS and peripheral tissues such as the adipose tissue, liver and muscle have shown 
promise over the past 100 years however withdrawal of these drugs recently [157]-[159] has resulted in the avoi- 
dance of harmful side effects to various obese individuals. The discovery of novel CNS compounds that are in the 
early phase and are under clinical development allows for assessment of agents that allow weight reduction with 
alteration in serious medical complications of obesity [160]-[164].  
 
 
Figure 2. Anti-obese drugs act at the central nervous system or 
peripheral nerous system to control food intake and body wei- 
ght.                                                  
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8. Mechanisms of Anti-Obesity Drugs 
Sympathomimetic drugs act as an appetite suppressant by increasing fullness and delaying food intake. These 
drugs act as the neurotransmitter norepinephrine and side effects include tachycardia and increase in blood 
pressure and are involved in significant weight loss in various clinical trials. Sympathomimetic drugs include 
benzphetamine, phendimetrazine, phentermine, diethylpropion, mazindol, sibutramine and phenylpropanolamine. 
Psychotropic drugs include the selective serotonin uptake inhibitors (e.g. fluoxetine, sertraline, fluvoxamine, and 
bupropion) used for weight loss in clinical trials and the treatment of mood disorders (antidepressants and an- 
tiepileptics). Drug induced weight gain [165] also includes a systematic review of intra-class and inter-class 
psychotropic drugs [166]-[168] that allow poor recommendations of various psychotropic drugs involved in 
weight gain and the induction of obesity. 
Drugs that inhibit fat absorption or digestion (pancreatic lipase inhibitors) have shown significant weight loss in 
obese individuals by altering metabolism of lipoproteins in the blood plasma. Weight loss was associated with 
decreases in low density lipoprotein (LDL) cholesterol, glucose and blood pressure (e.g. Orlistat which is a potent 
inhibitor of gastrointestinal lipase). Lipid digestion inhibitor (actinobacterium) inhibits the activity of pancreatic 
lipase one of the enzymes involved in fat digestion. Combinations in drug therapy have also been used to delay 
food intake and inhibit fat absorption to maintain weight loss in obese individuals. Anti-obesity drugs that treat 
obesity also involve the neurotransmitter receptors and currently the neurotransmitter receptors under evaluation 
include the cholecystokinin (CCK)1R agonist, cannabinoid receptor 1 (CB1R) inverse agonists and 5 hydroxy-
tryptamine receptor (5HT) 2cR agonist with the CB1 and 5HT agonists indicated in human trials to induce weight 
loss. Neuropeptide mimetics with peptides like leptin that reduces food intake have also been evaluated. 
Anti-obesity drugs that improve insulin resistance, dyslipidemia and the metabolic syndrome have not been 
appropriate to lifestyles, diet and health conditions and drug effectiveness has been variable without weight loss. 
Long term treatment of obesity with the use of anti-obese drugs particularly centrally active agents has not been 
achieved with safety concerns. Anti-obesity drug discovery programmes have been ineffective with improper 
starts, failures in clinical development, and withdrawals due to adverse effects that were never predicted from 
clinical trials and drug development. Removal of several of these drugs from the market [157]-[159] has allowed 
the introduction of other drugs such as gut based hormone treatments which target many pathways involved in 
the regulation of energy balance (Contrave or Emphatic). Development of new drugs that prevent NAFLD [169] 
and promote liver xenobiotic metabolism may manage and prevent adiposity. These new drugs that reduce xe-
nobiotic toxicity do not pose safety concerns. The long term use of these anti-obesity drugs prevents insulin re-
sistance, xenobiotic toxicity and the metabolic syndrome with cardiovascular safety. 
9. Nutritional Interventions Reverse NAFLD with the Prevention of Obesity 
In Western countries, the aging populations are afflicted with disorders of the SCN and appetite control that are 
closely related to endocrine abnormalities as observed in obesity and chronic diseases [10]. High fat foods that 
are consumed in these countries with low physical activity accelerate chronic diseases and neuroendocrine dis-
turbances in these obese and aged populations leading to the global obesity pandemic. Women and children may 
be at greater risk for obesity in Western populations with NAFLD with the metabolic syndrome more common 
in these groups. Consumption and identification of food components in diets that extend life have become im-
portant with reduction in xenobiotic toxicity associated with NAFLD and chronic diseases [170]-[177]. 
A low calorie diet is essential and recommended for the treatment of NAFLD and obesity and the benefit of 
this dietary regime is quite likely to lead to Sirt1 activation with improved peripheral cholesterol and xenobiotic 
metabolism. Sirt1 activation may also lead to the stability of the neuroendocrine system that allows control of 
brain appetite centres without abnormal sensations related to hunger and behavioural disorders associated with 
overeating. Appropriate changes in the consumption of various foods that improve Sirt1 and PXR activation are 
required and Sirt1 inhibitors such as alcohol should be avoided with low palmitic acid diets essential for treat-
ment of liver disease and for rapid liver metabolism of glucose, amino acids, xenobiotics and fatty acids. 
Prevention of chronic disease and activation of nuclear receptors such as Sirt1/PXR are essential for reversal 
of insulin resistance and endocrine disorders associated with obesity. Healthy food consumption and exercise 
may not eradicate the obesity epidemic or chronic diseases in the Western world since various xenobiotics being 
present in the food such as the phthalates which affect the nuclear receptors (PPAR-Sirt1) are possibly involved 
in hypothalamic disorders that are closely related to food intake and body weight [10] [14]. The role of diets that 
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contain fat soluble xenobiotics needs to be determined since consumption of various low fat foods may have re-
duced xenobiotics and drugs [169] that reduce intestinal lipophilic xenobiotics may reverse NAFLD, insulin re-
sistance and chronic diseases associated with obesity. Individuals from developed countries must undergo ex-
posure assessment in developing countries [14] to avoid xenobiotic toxicity from elevated xenobiotic exposure 
present in food, water and air with induction of chronic disease such as obesity. 
Effective diets for the prevention of NAFLD and chronic diseases utilise nutrients like methionine methylsul-
fonylmethane, sulphur, choline, and trimethylglycine as building blocks and allow switching of genes on and off 
to regulate appropriate cell function. Vitamins such as vitamin B12, folic acid, and vitamin B6 play multiple 
roles in the support of nuclear receptor stability. Foods that are important include eggs, cottage cheese, dairy, red 
meat, chicken, legumes, duck, nuts, and seeds. Consumption of fish oils (DHA/EPA) and melatonin are impor-
tant to the reversal of NAFLD with the consumption of phosphatidylinositol essential for nuclear receptor liver 
function and the reversal of NAFLD in man. Antioxidants and minerals (magnesium, zinc) that improve ge-
nomic stability and reduce free radical damage of cells include vitamins such as C, D and E essential for cell 
function. A lack of antioxidants leads to increased free radical damage and more risk for damage to various cells 
with chronic disease. Addition of resveratrol to the diet has been shown to activate Sirt1 with the prevention of 
NAFLD in animal models [178]. 
High fibre diets [179] that contain fruit and vegetables have become important for the treatment of NAFLD 
with the reduction in the fat content of tissues such as the liver and adipose tissue and prevention of various 
chronic diseases (Figure 3). Activation of nuclear receptors such as the Sirt1/PXR and G coupled receptors by 
calorie restriction (low glycemic index) is important to the science of nutrigenomics [179] with relevance of 
specific nutrients in the treatment of NAFLD and induction of obesity. Fruits such as apples contain pyruvic ac-
id (450 mg/apple) an antioxidant that is an activator of Sirt1 [180] [181] and is essential for NAFLD treatment. 
Consumption of pyruvic acid has been associated with weight loss [182]-[184] with therapeutic potential to the 
heart and brain [185] [186]. Other foods that contain small amounts of pyruvic acid such as cheese and red wine 
also contain inhibitors of Sirt1 (palmitic acid and alcohol respectively). Pyruvic acid carboxylase is connected to 
NAFLD with inhibition of pyruvic acid carboxylase a therapy for NAFLD and induction for obesity and di-
abetes [187]. 
Excessive ingestion of vegetables not more than (1 - 2 gm/day) may cause SCN disorders with accumulation 
of brain phytosterols with aging [179]. The phytosterols [179] that regulate liver cholesterol metabolism are 
critical to prevent and reverse NAFLD with HDL cholesterol metabolism closely linked to phytosterol ingestion 
[179]. Specific polyphenols found in vegetables and fruits need careful evaluation since high doses [188] [189] 
may cause increased oxidative stress with toxicity to the liver and induction of NAFLD and chronic disease. 
PXR and its role in liver regeneration [190], glucose/lipid metabolism and diets that activate PXR in the liver 
and periphery have become important to the prevention of NAFLD and obesity. Nutritional and therapeutic in-
terests in pyruvic acid consumption (6 - 44 g/day) have extended to leucine metabolism in man with conversion 
of pyruvic acid to leucine in plants but not in man. 
Leucine administration (Figure 3) has been shown to stimulate insulin release [191] [192] increase adiponec-
tin levels and reduce cholesterol levels in rats and glucose levels in obese mice [193]-[195]. Interest in leucine 
administration in man has increased with the effects of leucine on food intake and appetite control that involves 
the hypothalamus [196] [197]. Furthermore, leucine activation of the mTOR pathway [198] that is linked to 
growth and disease [199] may involve the GPCR leucine rich repeats in obesity [200] [201] with leucine effects 
regulated by Sirt1’s involvement in the inhibition of mTOR [202] [203]. The rapid metabolism of leucine in 
man with exercise [204]-[208] has become important to the induction of obesity with the essential role of leu-
cine in the prevention of NAFLD. Sirt1 downregulation has been shown to be associated with skeletal muscle 
insulin resistance [209]-[212] with the essentiality of pyruvic acid and leucine, isoleucine and valine in the 
maintenance and growth of muscles (skeletal and cardiac) and metabolism of obese tissue lipids. 
Furthermore, the SCN controls the circadian oscillators in peripheral tissues with leucine zipper transcription 
factors closely involved in xenobiotic metabolism and circadian rhythms [213] [214]. Diets high in fat have been 
shown to disrupt the circadian rhythms (SCN) and override leucine control of Sirt1/PXR interactions in the liver. 
Under fasting and exercise conditions, the high rate of leucine oxidation was found with leucine supplementa-
tion to be essential for obese individuals involved in exercise regimes for the reversal of xenobiotic toxicity in 
obesity [14]. Importance of dietary fibre in xenobiotic toxicity and metabolism has been reported [215] [216]  
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Figure 3. Nutritional interventions that target NAFLD prevent the induction 
of obesity.                                                        
 
with therapeutic leucine levels to maintain circadian control of liver glucose and insulin levels with the preven-
tion of NAFLD and induction of obesity that is reversible in the early stages of morbid obesity but irreversible in 
diabetes associated with severe SCN disorders [217]. Furthermore, alterations in circadian imbalances in obesity 
that affect liver and kidney xenobiotic metabolism may be related to eye diseases associated with photodamage 
and age-related light damage of the retina by xenobiotics [218] [219]. 
10. Conclusion 
There has been a rise in obesity worldwide over the past decades with an increase in obesity in both developed and 
developing countries. The complications of obesity are expected to rise and affect approx. 42% of the global 
population by the year 2030. The serious health problems include the diseases of the kidney, liver, pancreas, 
muscle, heart, eyes, gall bladder and brain. Several factors may be involved in the induction of obesity and include 
high fat/sugar diets, genetic predisposition, xenobiotic consumption, sleep deprivation, duration of drug exposure 
and various environmental factors such as behaviour and lifestyle that disrupt the SCN regulation of the endocrine 
and metabolic rhythms. Hepatic nutrient sensing nuclear receptor Sirt1 expression is dysregulated in obesity and 
may account for the global induction of obesity and various chronic diseases worldwide. The use of anti-obese 
drugs has been assessed in obesity with anti-obesity drug therapy involved in the induction of obesity and chronic 
disease. Diseases of the liver such as NAFLD and chronic kidney disease in obesity delay the metabolism of EDCs 
or POP that are closely linked to endocrine abnormalities, appetite dysregulation, cardiovascular disease, eye 
disease and neurodegeneration. The global health warnings have recommended various nutritional interventions 
with the consumption of high fibre diets that contain various food components such as pyruvic acid and leucine 
that may activate liver nuclear receptors (SIRT1/PXR) and reverse NAFLD with improvements in hepatic glucose, 
cholesterol and xenobiotic metabolism that are risk factors for disrupted SCN function that promote endocrine 
abnormalities in obesity and associated chronic diseases. 
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